TARGETING CHOLINERGIC SYNDROME IN PANCREATIC CANCER THROUGH NATURAL COMPOUNDS

Abstract

Pancreatic cancer is among the leading cancers worldwide responsible for the mortality rate increasing due to cancer deaths. The detection of pancreatic cancer is very difficult thus, making it the more fatal until the treatment for it begins. The treatment for the cancer includes immunotherapy, surgical resection and chemotherapy. Chemotherapy has always been in research for introducing better drugs for cancer therapy. Various chemotherapeutic drugs have been given approval by Food and Drugs Association [FDA]. These include Olaparib, irinotecan hydrochloride liposome, mitomycin, erlotinib, paclitaxel, gemcitabine [the first drug] among others which have proven to be beneficial for the treatment of pancreatic cancer. But these FDA approved drugs do have various side effects such as rash, diarrhea, vomiting, bradycardia, rhinitis, acute renal failure, hypotension and hypersalivation. In this article, the side effect which has been talked about is cholinergic syndrome which is a major side effect of onivyde [irinotecan hydrochloride liposome]. Thus, we need natural compounds to overcome these side effects which if not better are equivalent to these drugs. Through this research we are going to identify which drug suits the most with the FDA approved drugs by performing molecular docking. For performing docking, we underwent many steps from finding the structure to pharmacophore modelling which also will be mentioned in the paper. Isowogonin obtained from Didymocarpus pedicellata is the one which appeared to be the lead compound as it can be well tolerated with no or least side effects and considered as an alternative for various FDA approved drugs used in treatment of pancreatic cancer.